Published in Vaccine Weekly, July 5th, 2006
In the first oral presentation entitled, "A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA-4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (HRPC)," Cell Genesys and collaborator, Medarex, Inc., presented encouraging data from a Phase 1 clinical trial of the company's' GVAX immunotherapy for prostate cancer,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly